Fig. 1: Overview of the study cohort. | Blood Cancer Journal

Fig. 1: Overview of the study cohort.

From: Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort

Fig. 1

*Not included if not registered in both the Danish Lymphoma Registry and the Danish Pathology Registry. The study cohort consisted of a total of 3,146 patients diagnosed with FL in Denmark between 2005–2020. From these, patients with data registered eligible for the POD24 analyses were identified, resulting in 2389 cases. Thus, the final study cohort consisted of 1836 POD24-neg patients and 553 POD24-pos patients. 3B-FL primary diagnosis of FL grade 3B, dc-tFL discordant/composite transformed FL, DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, POD24 progression of disease within 24 months of diagnosis, nt-FL non-transforming FL, POD24-neg POD24-negative patients, POD24-pos POD24-positive patients, st-FL subsequently-transforming FL.

Back to article page